SEC Filings

10-K
ARRAY BIOPHARMA INC filed this Form 10-K on 08/11/2017
Entire Document
 

ITEM 6.     SELECTED FINANCIAL DATA

The following selected financial data is derived from our audited financial statements. These historical results do not necessarily indicate future results. You should read the selected financial data along with our financial statements and related notes, as well as "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" appearing elsewhere in this Annual Report on Form 10-K. Amounts are in thousands except per share data:
 
Year Ended June 30,
 
2017
 
2016
 
2015
 
2014
 
2013
Revenue
 
 
 
 
 
 
 
 
 
License and milestone revenue
$
19,844

 
$
3,876

 
$
20,367

 
$
25,111

 
$
56,726

Reimbursement revenue
107,197

 
107,330

 
7,020

 

 

Collaboration and other revenue
23,811

 
26,673

 
24,522

 
16,967

 
12,854

Total revenue
150,852

 
137,879

 
51,909

 
42,078

 
69,580

Operating expenses
 
 
 
 
 
 
 
 
 
Cost of partnered programs
35,395

 
23,166

 
44,392

 
45,965

 
30,078

Research and development for proprietary programs
178,199

 
160,655

 
54,442

 
49,824

 
59,420

General and administrative
39,336

 
36,267

 
31,433

 
21,907

 
19,624

Total operating expenses
252,930

 
220,088

 
130,267

 
117,696

 
109,122

Gain on the Binimetinib and Encorafenib Agreements, net

 

 
80,010

 

 

Gain on sale of CMC, net

 

 
1,641

 

 

Income (loss) from operations
(102,078
)
 
(82,209
)
 
3,293

 
(75,618
)
 
(39,542
)
Other income (expense)
 
 
 
 
 
 
 
 
 
Impairment loss related to cost method investment
(1,500
)
 

 

 

 

Realized gains on investments and other
897

 

 
16,255

 

 

Change in fair value of notes payable
(2,600
)
 

 

 

 

Loss on prepayment of long-term debt, net

 

 

 

 
(11,197
)
Interest income
796

 
243

 
68

 
77

 
55

Interest expense
(12,333
)
 
(10,874
)
 
(10,247
)
 
(9,716
)
 
(11,258
)
Total other income (expense), net
(14,740
)
 
(10,631
)
 
6,076

 
(9,639
)
 
(22,400
)
Net income (loss)
$
(116,818
)
 
$
(92,840
)
 
$
9,369

 
$
(85,257
)
 
$
(61,942
)
Weighted average shares outstanding – basic
163,207

 
142,964

 
136,679

 
123,403

 
107,794

Weighted average shares outstanding – diluted
163,207

 
142,964

 
141,692

 
123,403

 
107,794

Net earnings (loss) per share – basic
$
(0.72
)
 
$
(0.65
)
 
$
0.07

 
$
(0.69
)
 
$
(0.57
)
Net earnings (loss) per share – diluted
$
(0.72
)
 
$
(0.65
)
 
$
0.07

 
$
(0.69
)
 
$
(0.57
)

 
June 30,
 
2017
 
2016
 
2015
 
2014
 
2013
Cash cash equivalents and marketable securities
$
235,055

 
$
110,538

 
$
178,822

 
$
111,638

 
$
108,706

Working capital
200,626

 
102,867

 
148,623

 
68,943

 
70,732

Total assets
279,145

 
168,900

 
198,207

 
136,625

 
133,335

Long-term debt, net and notes payable
133,905

 
113,655

 
107,280

 
101,524

 
96,368

Total stockholders' equity (deficit)
11,727

 
(37,932
)
 
42,653

 
(25,721
)
 
(21,909
)


57